CPX-351+GO in Subjects 55 Years Old, or Older, With AML

Model scores of the 29,894 trials active now.

Model score 21% for any early termination, 9% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-09-01. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: chemotherapyevidencepriortherapysubjects with
  Phrases that lowered it: efficacyaminotransferaseand safetycombinationclinical
• Sponsor's past termination rate: 25.3% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Minimum age: 55 (lowers risk) · Who can join
• Design: single group (raises risk) · Design
• Drug's FAERS reports with a death: 37.0% (raises risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 58 (lowers risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 96.2% (raises risk) · Drug's FDA history
• Sponsor's past trials: 245 (lowers risk) · Sponsor's track record
• Collaborators: 2 (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Number of arms: 3 (lowers risk) · Design
• Responsible party: sponsor (lowers risk) · Design
• Maximum age: not given (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia NCT04075747 · started 2019 · scored riskier than 58% of active trials completed
• Clinical Trial to Assess the Efficacy and Toxicity of Induction and Consolidation With CPX-351 for Patients Aged 60 to 75 Years With Secondary or High-risk Acute Myeloid Leukemia NCT04230239 · started 2019 · scored riskier than 63% of active trials completed
• Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia NCT01696084 · started 2012 · scored riskier than 87% of active trials completed
• Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia. NCT04425655 · started 2020 · scored riskier than 98% of active trials terminated
• Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia NCT01435343 · started 2012 · scored riskier than 99% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.